impression healthcare - search results

If you're not happy with the results, please do another search
Impression Healthcare ASX IHL oral devises cannabinoid product sales COVID-19

Impression Healthcare to focus exclusively on cannabinoid sales and drug development

Medical cannabis company Impression Healthcare (ASX: IHL) has announced it will discontinue sales of its oral devices by the end of the month to focus its resources exclusively on cannabinoid sales an...
Impression Healthcare CBD drug trial leading cause of COVID-19 deaths ASX IHL acute respiratory distress syndrome

Impression Healthcare starts CBD drug trial to fight leading cause of COVID-19 deaths

Impression Healthcare (ASX: IHL) has begun the first clinical trial to assess the effectiveness of its cannabidiol (CBD) based drug IHL-675A against sepsis associated acute respiratory distress syndro...
Impression Healthcare ASX IHL rugby league footballer James Graham

Impression Healthcare recruits NRL star James Graham to boost commercial development of IHL-216A

Medical cannabis company Impression Healthcare (ASX: IHL) has unveiled a high profile acquisition in the form of professional rugby league footballer James Graham. In a statement to the market this m...
Impression Healthcare animal testing CBD drug COVID-19 related respiratory conditions ASX IHL

Impression Healthcare to commence animal testing of CBD drug for COVID-19 related respiratory conditions

Impression Healthcare (ASX: IHL) has confirmed in it quarterly report that it has sourced all permits and products required for the start of animal pre-clinical testing of cannabinoid drug IHL-675A de...
Impression Healthcare ASX IHL 2024 commercialisation cannabinoid treatment traumatic brain injury

Impression Healthcare targets 2024 commercialisation of cannabinoid treatment for traumatic brain injury

Medical cannabis company Impression Healthcare (ASX: IHL) has confirmed plans to bring its novel cannabinoid formula IHL-216A for patients with traumatic brain injury to the prescription market within...
Impression Healthcare Hydroxychloroquine CBD cannabis COVID-19 coronavirus induced ARDS Adult Respiratory Distress Syndrome

Impression Healthcare develops CBD-based drug as potential treatment for coronavirus symptoms

Medicinal cannabis company Impression Healthcare (ASX: IHL) has developed a cannabidiol (CBD) based drug that it believes holds potential for the treatment of coronavirus-induced respiratory distress ...
Impression Healthcare FDA cannabinoid drug candidate IHL-42X Camargo Pharmaceuticals ASX IHL

Impression Healthcare sets out FDA approval strategy for cannabinoid drug candidate IHL-42X

Medical cannabis company Impression Healthcare (ASX: IHL) has revealed it has received an independent strategic assessment report on the FDA approval pathway for cannabinoid IHL-42X from US-based Cama...
Impression Healthcare CBD inhalers Australia Special Access Scheme lung inflammation COVID-19 coronavirus Asthma COPD Ventilin

Impression Healthcare acquires CBD inhalers for distribution under Australia’s Special Access Scheme

Medical cannabis company Impression Healthcare (ASX: IHL) came out of a trading halt late this morning to unveil an initial order for cannabidiol (CBD) pressurised metered-dose inhalers (similar to an...
Impression Healthcare ASX IHL traumatic brain injury medicinal cannabis

Impression Healthcare to launch medical cannabis trials for treatment of traumatic brain injury

Australian medical cannabis company Impression Healthcare (ASX: IHL) has finalised the design of a clinical program to assess novel cannabinoid formula IHL-216A on neurocognitive function after trauma...
Impression Healthcare Incannex cannabinoid oil sales ASX IHL Cannvalate

Impression Healthcare expands cannabinoid oil sales program

Medical cannabis company Impression Healthcare (ASX: IHL) has expanded its cannabinoid oil sales program that runs side by side with its extensive base of clinical trial projects. In a statement to...
Impression Healthcare ASX IHL obstructive sleep apnoea clinical trial

Impression Healthcare prepares for obstructive sleep apnoea clinical trial

Medical cannabis company Impression Healthcare (ASX: IHL) is on course to begin a clinical trial using its IHL-42X drug candidate for the treatment of obstructive sleep apnoea. The drug was recentl...
Impression Healthcare ASX IHL files patent non-intrusive treatment obstructive sleep apnoea pill

Impression Healthcare files patent for non-intrusive treatment of obstructive sleep apnoea

Medical cannabis company Impression Healthcare (ASX: IHL) is continuing on its path to developing an effective solution for obstructive sleep apnoea (OSA) having filed a patent application covering IH...
Impression Healthcare ASX IHL John Michailidis Incannex cannabinoid pharmaceutical

Impression Healthcare recruits Big Pharma executive to complete cannabinoid drug discovery goal

Medical cannabis company Impression Healthcare (ASX: IHL) has continued its top-tier recruitment drive with the addition of yet another pharmaceutical industry expert into its ranks. Former Roche (...
Impression Healthcare IHL ASX cannabis Dr Sud Agarwal Incannex AGM presentationvideo

Impression Healthcare AGM presentation from chief medical officer Dr Sud Agarwal

Dr Sud Agarwal presented at Impression Healthcare's (ASX: IHL) annual general meeting on Friday 4th October 2019 to discuss Incannex's portfolio. Under the guidance of Impression's new medical advi...
Impression Healthcare ASX IHL cannabidiol head trauma

Impression Healthcare files patent application for medicinal CBD drug to alleviate concussion injuries

Impression Healthcare (ASX: IHL) has opted to file a patent application for a neuroprotective agent that could potentially aid people that suffer concussions – a growing issue in contact sports such a...
Impression Healthcare ASX IHL medical advisory board wholesale order Incannex CBD oils

Duo of renowned specialists join Impression Healthcare, Incannex CBD oils on route

Following a busy few months on the recruitment and brand licencing fronts, Impression Healthcare (ASX: IHL) has appointed an additional duo of leading medical experts to its Medical Advisory Board, ov...
Impression Healthcare ASX IHL medical advisory board Rondhir Jithoo Simon Hinckfuss

Impression Healthcare appoints two globally renowned medical experts for cannabis medicines projects

Impression Healthcare (ASX: IHL) has bolstered its Medical Advisory Board by appointing two leading medical experts possessing extensive expertise within two key market niches currently being explored...

Impression Healthcare commences obstructive sleep apnoea clinical trial

Following last week’s deal that saw Impression Healthcare (ASX: IHL) secure the cannabinoid materials it needs to conduct a series of clinical trials, the cannabis company has announced that it has su...
Impression Healthcare ASX IHL Incannex Pharmaceuticals medicinal cannabis oil supply cannabinoid

Impression Healthcare secures long term oil supply agreement, unveils new cannabis discovery brand Incannex

Impression Healthcare (ASX: IHL) has moved to extend its medicinal cannabis market coverage after unveiling the all-new cannabinoid drug discovery brand Incannex Pharmaceuticals. As a new entity, I...
ONE Championship Impression Healthcare ASX IHL mouthguard concussion research CBD

Impression Healthcare becomes official supplier and research partner to ONE Championship

Barely a week after Aurora announced a deal with the Ultimate Fighting Championship (UFC), Australia’s very own Impression Healthcare (ASX: IHL) has made a move that emulates one of Canada’s most prom...
Dr Sud Agarwal Impression Healthcare ASX IHL Cannvalate cannabis

Impression Healthcare appoints leading medicinal cannabis pioneer Dr Sud Agarwal to its board

Impression Healthcare (ASX: IHL) has tweaked its internal structure by appointing Dr Sud Agarwal, a leading figure in the medicinal cannabis industry as its chief medical officer and non-executive dir...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS